Prodrugs for a selective cancer therapy

Details Prodrugs for a selective cancer therapy Prodrugs for a selective cancer therapy

2007-05-08

2007-05-08

Solola, Taofiq (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S411000, C546S108000, C548S433000, C548S439000

Reexamination Certificate

active

10275415

ABSTRACT:
The chemotherapy of malignant tumours is greatly restricted by the generally slight differentiation of the available cytostatic agents between normal and malignant tissue. In order to achieve an improvement of the selectivity in cancer therapy, novel prodrugs have been developed from 6-hydroxy-2,3-dihydro-1H-indolene, 5-hydroxy-1,2-dihydro-3H-pyrrolo[3,2-e]indolene and 5-hydroxy-1,2-dihydro-3H-benzo[e]indolene as well as from 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]-quinolines, that may be used within the framework of the ADEP therapy (antibody directed enzyme prodrug therapy). The new prodrugs are characterised by a high difference in toxicity between the prodrug and underlying drug and by a very high efficacy of the drug. After splitting off of the glycosidic and/or acetal group on the phenolic hydroxy groups of the prodrugs, a spirocyclopropacyclohexadiene is formed which, being a highly toxic group, effects an alkylation of the DNA or RNA.

REFERENCES:
patent: 5646298 (1997-07-01), Powell
patent: WO 97/44000 (1997-11-01), None
patent: WO 98/11101 (1998-03-01), None
Tietze, L.F. et al.: “Prodrugs of the cytostatic CC-1065 that can be activated in a tumor-selective manner” Angew. Chem. Int. Ed., Bd. 35, 1996, Seiten 2674-7, XP002183014 in der Anmeldung erwähnt das ganze Dokument.
Ling, Lei et al.: “A practical route to optically active CBI, a potent analog of the CC-1065 alkylation subunit”. Heterocycl. Commun. (1997), 3(5), 405-408, 1997, XP001055518, s. Verbindung auf Seite 406.
Muratake, Hideaki et al.: “A novel phenol-forming reaction for preparation of benzene, furan, and thiophene analogs of CC-1065/duocarmycin pharmacophores” Tetrahedron Lett. (1997, 28(43), 7577-7580, 1997, XP004125300, s. Verbindung 29 auf Seite 7579.
Aristoff, Paul A. et al.: “Synthesis and biochemical evaluation of the CBI-PDE-I-dimer, a benzannelated analog of (+)-CC-1065 that also produces delayed toxicity I mice”. J. Med Chem. (1993), 36(14), 1956-63, 1993, XP000910185. s. Verbindung 12 auf Seite 1957.

Affiliated with

Also associated with

Rating

Prodrugs for a selective cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs for a selective cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs for a selective cancer therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3760047